CRYL1

CRYL1 encodes a metabolic enzyme of the 3-hydroxyacyl-CoA dehydrogenase family, defined by two HCDH domains including a putative NAD/FAD-binding domain and 83% identity to rabbit lambda-crystallin, with mRNA expression concentrated in liver and kidney (PMID:12527201). It functions as a candidate tumor suppressor: its expression is downregulated in the majority of hepatocellular carcinomas and lost through homozygous deletion and LOH at 13q12.11, where loss correlates with early-onset disease (PMID:12527201, PMID:16075462). In clear cell renal cell carcinoma, CRYL1 overexpression suppresses proliferation, colony formation, and migration and induces apoptosis, acting at least in part through upregulation of the calcium-sensing receptor CASR, whose knockdown partially reverses the anti-migratory phenotype, and in xenografts shifts the cell toward a pro-apoptotic, anti-invasive program (elevated BAX and TIMP3, reduced BCL2 and MMP9) (PMID:42105605). Independently of any protein function, the CRYL1 genomic locus harbors cis-regulatory elements required for cochlear GJB2 expression: deletions spanning CRYL1 in trans with pathogenic GJB2 variants cause DFNB1A nonsyndromic sensorineural hearing loss by abolishing cis GJB2 expression (PMID:40565562, PMID:19101659, PMID:41367487). The enzymatic activity inferred from its HCDH domains has not been directly assayed in the available corpus.

1. 2003 Medium

   Establishing the molecular identity of CRYL1 was the first step: the question was what kind of protein it encodes and where it acts, answered by domain architecture and tissue expression.

   Evidence cDNA cloning, sequence/domain analysis, and Northern blot expression profiling

   PMID:12527201

   Open questions at the time

   • Enzymatic activity was inferred from domain homology, not directly assayed
   • No substrate identified
   • No structural model of the HCDH domains
2. 2003 Low

   Whether CRYL1 expression is altered in cancer was addressed by showing downregulation in a majority of hepatocellular carcinomas, raising the tumor suppressor hypothesis.

   Evidence Differential gene expression analysis between HCC and normal liver tissue

   PMID:12527201

   Open questions at the time

   • Expression-level association only; no functional mechanism tested
   • Does not establish causality or the basis of downregulation
3. 2005 Medium

   The genetic basis of CRYL1 loss in liver cancer was clarified by mapping homozygous deletion and LOH at 13q12.11, supporting a candidate tumor suppressor at this locus.

   Evidence Genetic marker scan, Southern blotting, LOH analysis, and quantitative RT-PCR in HCC tissue pairs

   PMID:16075462

   Open questions at the time

   • No direct functional assay of CRYL1 protein in HCC
   • Deletion spans multiple genes (TG737, GJB2), confounding gene-specific attribution
4. 2017 Medium

   A recurrent CRYL1-IFT88 fusion transcript in HCC raised the possibility that CRYL1 locus rearrangement contributes to tumorigenesis by disrupting IFT88.

   Evidence Transcriptome sequencing, RT-PCR validation, and 5'/3' RACE characterization

   PMID:28489570

   Open questions at the time

   • Functional consequence for IFT88 inferred bioinformatically, not tested experimentally
   • Role of the retained CRYL1 portion in the fusion unknown
5. 2017 Low

   Whether CRYL1 responds to environmental stress was probed by showing cadmium-inducible expression in zebrafish retina, hinting at a redox-related stress role.

   Evidence In situ hybridization and dose-response analysis in cadmium-exposed zebrafish

   PMID:28385620

   Open questions at the time

   • Single method (ISH); functional mechanism not tested
   • No link to the proposed enzymatic activity established
6. 2025 High

   The hearing-loss phenotype of CRYL1 deletions was resolved as a positional/cis-regulatory effect rather than loss of CRYL1 protein, showing the locus carries elements required for cochlear GJB2 expression.

   Evidence Panel NGS, MLPA, whole-genome breakpoint mapping, and Sanger sequencing across multiple independent deletions in trans with GJB2 variants

   PMID:19101659 PMID:40565562 PMID:41367487

   Open questions at the time

   • Precise regulatory elements and their interaction with GJB2 not mapped at base resolution
   • Does not implicate CRYL1 protein function in hearing
7. 2026 Medium

   A functional tumor suppressor mechanism was finally provided by showing CRYL1 overexpression suppresses ccRCC growth and migration via upregulation of CASR.

   Evidence In vitro proliferation/migration/apoptosis assays, transcriptome sequencing, CASR-knockdown rescue, IHC, and xenograft models

   PMID:42105605

   Open questions at the time

   • Single lab; rescue was only partial, implying additional effectors
   • Mechanism linking CRYL1 enzymatic activity to CASR transcription unknown
   • Whether the same axis operates in HCC not tested

• The direct biochemical activity of CRYL1 and how it mechanistically connects to tumor suppression and downstream CASR signaling remain unresolved.
• No enzymatic substrate or catalytic readout demonstrated
• Causal chain from a metabolic/redox activity to CASR upregulation unknown
• No structural characterization